AMOXICILLIN AND CLAVULANATE POTASSIUM

Post-LOE

amoxicillin and clavulanate potassium

Aurobindo Pharma

ANDAORALFOR SUSPENSION9 Generics Approved

Approved

Apr 2019

Lifecycle

Post-LOE

Competitive Pressure

60/100

Data completeness

3/8 — Basic

AMOXICILLIN AND CLAVULANATE POTASSIUM (amoxicillin and clavulanate potassium) by Aurobindo Pharma is [see microbiology ( )]. Approved for equal to 40 kg with: recurrent, persistent acute otitis media due to s, acute otitis media due to s and 4 more indications. First approved in 2019.

Mechanism of Action

[see Microbiology ( )].

Indications (7)

equal to 40 kg with: Recurrent persistent acute otitis media due to S acute otitis media due to S

Worked on AMOXICILLIN AND CLAVULANATE POTASSIUM at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.